透景生命 (300642)
Tellgen Corporation
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 16254.40
- Circulating A-Shares(W): 13770.70
- Earnings Per Share(RMB): 0.0356
- Net Assets Per Share(RMB): 9.0496
- Operating Revenue(W RMB): 25761.32
- Total Profit(W RMB): 311.79
- Net Profit Attributable to Parent(W RMB): 577.49
- Net Profit Growth Rate(%): -76.33
- Weighted Return on Equity(%): 0.3800
- Operating Cash Flow Per Share(RMB): 0.6340
- Undistributed Profit Per Share(RMB): 4.8557
- Capital Reserve Per Share(RMB): 3.0175
2. Main Business
The main business covers:
- Research, production and sales of self-branded in vitro diagnostic products
3. Company Basic Information
- Company Name: Tellgen Corporation
- Listing Date: 2017-04-21
- Industry: Pharmaceutical Manufacturing
- Address: Building 1, No. 115, Lane 572, Bibo Road, China (Shanghai) Pilot Free Trade Zone
- Website: www.tellgen.com
- Company Profile: The company was established by the overall change of Tellgen Limited into a joint stock limited company. On December 5, 2014, the board of directors of Tellgen Limited reviewed and agreed that all shareholders of Tellgen Limited would act as promoters, based on the net assets of Tellgen Limited of RMB 107,451,353.94 as of June 30, 2014 audited by Lixin Certified Public Accountants, converted into shares at a ratio of 1:0.4188 to form 45,000,000 shares, with the remaining RMB 62,451,353.94 included in the capital reserve of the joint stock company, and the overall change into a joint stock limited company. On December 5, 2014, Lixin Certified Public Accountants verified the above-mentioned capital contribution and issued the Xinhui Shi Bao Zi [2014] No. 114720 "Capital Verification Report". On January 6, 2015, the Shanghai Municipal Commission of Commerce issued the "Approval of the Municipal Commission of Commerce on the Restructuring of Shanghai Tellgen Life Technology Co., Ltd. into a Joint Stock Limited Company" (Hu Shang Wai Zi Pi [2015] No. 2), agreeing to the overall change of Tellgen Limited into a joint stock limited company and renaming it "Shanghai Tellgen Life Technology Co., Ltd.", and agreeing to the "Sponsor Agreement" and "Articles of Association" signed by the company's promoters on December 5, 2014. On January 6, 2015, the issuer obtained the "Approval Certificate for Foreign-invested Enterprises of the People's Republic of China" (Shang Wai Zi Hu Gu Fen Zi [2012] No. 0320) issued by the Shanghai Municipal People's Government. On February 11, 2015, the company completed the industrial and commercial change registration at the Shanghai Administration for Industry and Commerce and obtained the business license with registration number 310115000800703.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Lingfei Group Co., Ltd. | General Legal Person | 1203.58 | 8.74 |
| 2 | Shanghai Pudong New Star Newstar Venture Capital Co., Ltd. | General Legal Person | 768.37 | 5.58 |
| 3 | Zhuhai Abama Private Fund Management Co., Ltd. - Abama Yuanxiang Hongli No. 57 Private Securities Investment Fund | Private Securities Investment Fund | 588.40 | 4.27 |
| 4 | CITIGROUP GLOBAL MARKETS LIMITED | QFII | 197.62 | 1.44 |
| 5 | GF Healthcare Equity Securities Investment Fund Class A | Fund | 195.35 | 1.42 |
| 6 | GF Pharmaceutical Health Hybrid Securities Investment Fund Class A | Fund | 189.88 | 1.38 |
| 7 | Great Wall Pharmaceutical Industry Selected Hybrid Initiated Securities Investment Fund Class A | Fund | 176.17 | 1.28 |
| 8 | Invesco Great Wall Healthcare Hybrid Securities Investment Fund Class A | Fund | 139.24 | 1.01 |
5. Concept Sectors
- Shanghai Free Trade Zone
- Gene Concept
- Assisted Reproduction
- Innovative Drugs
- DeepSeek
- AI Healthcare
- Low-Profit Stocks
- QFII New Entry
- Fund Increased Holdings
- Specialized and Sophisticated SMEs
- Micro and Small Cap Stocks
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information